Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.

A FIRST-IN-HUMAN PHASE 1/2 OPEN-LABEL STUDY OF INTRAVENOUS ST 067, SUBCUTANEOUS ST-067 WITH OR WITHOUT OBINUTUZUMAB PRE TREATMENT, AND ST-067 IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES